Novo Nordisk expands phase III program of obesity tablet treatment
![Photo: Tidsvilde Stine/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14491603.ece/ALTERNATES/schema-16_9/20160929-062243-pf-4928x2770ma%2520(3).jpg)
Novo Nordisk has chosen to expand a crucial, ongoing phase III program with GLP-1 analog semaglutide formulated as a tablet for people with severe obesity, the pharmaceutical company confirms to MedWatch in a written response.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk starts crucial trial of obesity tablet
For subscribers
New Novo Nordisk treatment targets 25% weight loss
For subscribers